Lupus & antiphospholipid syndrome
Targeting type I interferon in lupus autoimmune haemolytic anaemia: first report with anifrolumab
Authors' conclusion
In our cohort, ANF treatment was associated with a rapid and sustained increase in Hb levels, evident already at 1 month and progressively improving up to 6 months.
Study context
- Population
- Patients with SLE and active autoimmune haemolytic anaemia (AIHA) (positive direct Coombs test and laboratory evidence of active haemolysis) at anifrolumab initiation6F/1M
- Participants
- 7 patients
- Outcome
- Haemoglobin (Hb) levels vs baseline during ANF treatment
- Follow-up
- 3 months
Methodological detailsData collected at baseline (T0), after 1 month (T1) and every 3 months thereafter
- Data collected at baseline (T0), after 1 month (T1) and every 3 months thereafter
Main finding
As reported in the abstract
- Progressive increase in haemoglobin (Hb) levels, statistically significant difference compared with baseline after 3 months of treatment
- p=0.02
Observational data: associations, not effects.
Further findings
Overall disease activity (mean SLEDAI-2K) · up to 6 months
- Significant reduction of mean SLEDAI-2K values vs baseline
- P = 0.01
Original publication
Targeting type I interferon in lupus autoimmune haemolytic anaemia: first report with anifrolumab. Lupus Sci Med. Published 27 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →